| DB01254 | Dasatinib | For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. |
| DB01259 | Lapatinib | Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma. |
| DB00908 | Quinidine | For the treatment of ventricular pre-excitation and cardiac dysrhythmias |
| DB06589 | Pazopanib | Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
| DB00818 | Propofol | Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. |
| DB08820 | Ivacaftor | When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [L768, FDA Label].
When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. |
| DB01764 | Dalfopristin | For the treatment of bacterial infections (usually in combination with quinupristin). |
| DB01369 | Quinupristin | For the treatment of bacterial infections (usually in combination with dalfopristin). |
| DB08827 | Lomitapide | Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C). |
| DB09073 | Palbociclib | Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. |
| DB06717 | Fosaprepitant | For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. |
| DB09238 | Manidipine | For the treatment of hypertension. |
| DB11767 | Sarilumab | Indicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate. |
| DB13941 | Piperaquine | For the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with [DB11638]. |
| DB12332 | Rucaparib | Indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. |
| DB00501 | Cimetidine | For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion. |
| DB00921 | Buprenorphine | For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence. |
| DB01173 | Orphenadrine | Indicated for the treatment of Parkinson's disease. |
| DB00188 | Bortezomib | For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies. |
| DB00289 | Atomoxetine | For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures. |
| DB00744 | Zileuton | For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. |
| DB04839 | Cyproterone acetate | For the palliative treatment of patients with advanced prostatic carcinoma. |
| DB00304 | Desogestrel | For the prevention of pregnancy in women who elect to use this product as a method of contraception. |
| DB00458 | Imipramine | For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label].
May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904]. |
| DB06791 | Lanreotide | Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2) |
| DB00104 | Octreotide | For treatment of acromegaly and reduction of side effects from cancer chemotherapy |
| DB06663 | Pasireotide | For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option. |
| DB09099 | Somatostatin | For the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established. |
| DB04894 | Vapreotide | For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea. |
| DB11703 | Acalabrutinib | Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy [FDA Label]. |
| DB05928 | Dovitinib | Investigated for use/treatment in multiple myeloma and solid tumors. |
| DB08864 | Rilpivirine | Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm3.[L1030] The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031] |
| DB01128 | Bicalutamide | For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. |
| DB00215 | Citalopram | For the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label]. |
| DB00476 | Duloxetine | For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women. |
| DB01175 | Escitalopram | Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients. |
| DB04884 | Dapoxetine | For the treatment of premature ejaculation. |
| DB01098 | Rosuvastatin | Used as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease. |
| DB01054 | Nitrendipine | For the treatment of mild to moderate hypertension |
| DB00349 | Clobazam | For treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy. |
| DB09078 | Lenvatinib | Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. |
| DB04920 | Clevidipine | For the treatment of hypertension. |
| DB00370 | Mirtazapine | For the treatment of major depressive disorder. |
| DB00455 | Loratadine | A self-medication that is used alone or in combination with pseudoephedrine sulfate for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients (not for children under 6 unless directed by a clincian). |
| DB00778 | Roxithromycin | Used to treat respiratory tract, urinary and soft tissue infections. |
| DB01016 | Glyburide | Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone. |
| DB04794 | Bifonazole | Used for the treatment of various topical fungal infections, including athlete's foot (tinea pedis). |
| DB00898 | Ethanol | For therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated. |
| DB01321 | Josamycin | For the treatment of bacterial infections. |
| DB00316 | Acetaminophen | For temporary relief of fever, minor aches, and pains. |
| DB02701 | Nicotinamide | Not Available |
| DB00763 | Methimazole | For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis. |
| DB09036 | Siltuximab | Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive. |
| DB09063 | Ceritinib | Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. |
| DB09330 | Osimertinib | Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy. |